A range of products of non- animal origin

Level of protein lower than 5µg/g :
one of the lowest protein contents of all the products on the market.¹

A level of bacterial endotoxins strongly lower than the requirements of European Pharmacopoeia.²

Monophasic and homogeneous gel.

° rotation and ergonomic plunger : a syringe designed especially for Teosyal®.

25 mg/g : one of the highest hyaluronic acid concentrations in the market.

2 syringes of 1 mL in a box.

Reduced risk of hypersensitive reactions.³

Limited risks of inflammation, redness and oedema. Less hydroxyl radicals, major factor of hyaluronic acid degradation > Enhanced duration.

Gradual, more steady degradation. Less vulnerability to hydroxyl radicals.

Enhanced injection procedure and dosage control.

Optimal viscoelasticity for effective and durable filling.

Full correction, excellent results.

1- Data provided by the manufacturer on 24 consecutives batches.

2- Specifications of current European Pharmacopoeia (5th Ed.) require for hyaluronic acid gels for intradermal injection at the concentration of 25 mg/g (like Teosyal®) a bacterial endotoxin level lower than 12,5 EU/g (E.U. = Endotoxin Unit). Bacterial endotoxins are measured on each Teosyal® batch. Value measured on 30 consecutive batches: <0,2 EU/g. Measures have been performed by an independent GLP laboratory certified by AFFSaPS, Swissmedic and FDA.

3- Fridman P.M., Mafong E.A., Kauvar A.N.B., Geronemus R.G. Safety data of injectable non-animal stabilized hyaluronic acid gel for soft-tissue augmentation Dermatol. Surg., 2002, 28 (6), 491-494.